AbCellera Biologics (NASDAQ:ABCL) (NASDAQ:ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. Leveraging a proprietary single-cell screening platform, advanced microfluidics, and machine learning algorithms, the company accelerates the identification of antibody candidates against a broad range of disease targets. Its technology aims to streamline early‐stage drug discovery by rapidly isolating potent and specific antibodies from natural immune responses.
Founded in 2012 and headquartered in Vancouver, British Columbia, AbCellera has built a high-throughput laboratory infrastructure to support its antibody discovery efforts. The company emerged from academic research at the University of British Columbia, translating cutting-edge immunology and bioengineering into a commercial platform. Over the years, it has expanded its R&D capabilities with additional facilities in the San Francisco Bay Area, strengthening its presence in both Canadian and U.S. biotech hubs.
AbCellera’s services include antigen assay development, single-cell screening, lead optimization and antibody engineering. The company collaborates with pharmaceutical and biotechnology partners to co-develop therapeutics against infectious diseases, oncology, immunology and other areas of unmet medical need. Notably, AbCellera formed a high-profile partnership with Eli Lilly to develop bamlanivimab, a neutralizing antibody for COVID-19, demonstrating its capacity to respond to global health challenges on accelerated timelines.
Serving clients across North America, Europe and Asia, AbCellera maintains strategic alliances with both large pharmaceutical companies and emerging biotech firms. Under the leadership of co-founder and CEO David J. Johnston, the company continues to invest in artificial intelligence and automation to enhance throughput and data analytics. As it scales its proprietary platform, AbCellera aims to remain at the forefront of antibody discovery, enabling partners to bring innovative biologic therapies to market more efficiently.
